Le Lézard
Classified in: Health
Subject: PLW

ResMed's European Patents Infringed by Fisher & Paykel in Germany



SAN DIEGO, Oct. 6, 2017 /PRNewswire/ -- ResMed (NYSE: RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today announced the following updates in its ongoing global patent infringement litigation with Fisher & Paykel:

"ResMed will continue to stand against those we believe have unlawfully violated our patents," said ResMed global general counsel and chief administrative officer David Pendarvis. "We have more than 5,000 patents in our portfolio, reflecting three decades and millions of dollars of sustained investment in research and development, focused on ensuring that patients around the world receive the high-quality care they deserve. We're confident, as we've seen in these early rulings, that ResMed will ultimately prevail against Fisher & Paykel."

About ResMed

ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world's best tech-driven medical device company ? improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com | Facebook | Twitter | LinkedIn

For media:

For investors:

Alison Graves

Agnes Lee

+1 858-836-6789

+1 858-836-5971

news@resmed.com 

investorrelations@resmed.com





ResMed Inc. logo. (PRNewsFoto/ResMed Inc.)

 

SOURCE ResMed Inc.


These press releases may also interest you

at 05:01
CHESHAM, England, October 18, 2017 /PRNewswire/ -- The Netherlands Cancer Institute (NKI) announced today that it has received funding from the Dutch Cancer Society (KWF Kankerbestrijding) to test whether a novel molecular imaging technology can...

at 05:00
NEW YORK, Oct. 18, 2017 /PRNewswire/ -- Graham-Pelton Consulting Inc., a leading global fundraising and management consulting firm serving the nonprofit sector, announced today the appointment of Stuart P. Sullivan as senior vice president. During...

at 05:00
GREENWICH, Conn., Oct. 18, 2017 /PRNewswire/ -- Elsa Raskin, MD is proud to announce that she is the only plastic surgeon in Greenwich, CT to offer Profound by Syneron Candela. Profound is a groundbreaking treatment that reverses aging skin by...

at 05:00
FELTON, California, October 18, 2017 /PRNewswire/ -- The global deep brain stimulators (DBS) market size in 2016 was worth USD 618.6 million and is anticipated to grow with a CAGR 17.2% throughout the forecast period. The growth can be attributed...

at 04:00
YOKNEAM, Israel, October 18, 2017 /PRNewswire/ -- Presenters will feature results of recent successful studies using the innovative technology and its unique operative technique.  Lumenis Ltd., the world's largest energy-based medical device...

at 04:00
SAN FRANCISCO, October 18, 2017 /PRNewswire/ -- The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and...




News published on 6 october 2017 at 04:53 and distributed by: